Background
In untreated HIV disease, more than 10 years can elapse from initial infection to the first occurrence of an opportunistic infection (OI), an indicator that the disease has progressed to AIDS (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2006) . This period of time does not mean, however, that people infected with HIV who have not yet progressed to AIDS are symptom free. Existing definitions and care guidelines that categorize patients as ''asymptomatic'' may lead clinicians to ignore symptoms that are not directly related to OIs, but that do require attention.
In 1986, the Centers for Disease Control (CDC) (''Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections, '' 1986) provided an early description of HIV disease, which included two main categories: symptomatic and asymptomatic. For two decades, these definitions have been incorporated into treatment guidelines that have informed clinicians in the USA and other countries in their care for patients.
In the mid-1990s, with the ability to treat HIV itself, many clinicians began focusing solely on CD4 counts and symptoms directly related to OI (e.g. diarrhea, night sweats, fever). There has been growing evidence, however, that HIV-positive people experience many symptoms that are not directly related to OI or CD4 counts, particularly fatigue, depression, muscle aches, and fear/worries (Corless, Nicholas, Davis, Dolan, & McGibbon, 2002; Corless et al., 2008; Eller et al., 2005; Kemppainen et al., 2006; Voss, Portillo, Holzemer, & Dodd, 2007; Voss, 2005) . These symptoms often go unrecognized and untreated by health care providers (Hughes, 2004) , either because care providers do not ask patients about their symptoms or because they consider the symptoms to be ''sub-clinical''. Siegel, Schrimshaw, and Dean (1999) reported that having symptoms, as well as their intensity, influenced decisions to seek care and have contributed to reduced adherence to medications, thereby increasing the likelihood of resistance to medication regimens and exacerbating symptoms. These factors may also reduce the physical and mental aspects of a person's quality of life (Abel & Painter, 2003; Ammassari et al., 2001; Corless et al., 2002; Hudson, Kirksey, & Holzemer, 2004; Lorenz, Cunningham, Spritzer, & Hays, 2006) .
The aim of this study is to determine whether there are differences in the frequency and intensity of self-reported HIV symptoms among three levels of CD4 count (B200 cells/mm 3 , 200Á350 cells/mm 3 , 350 cells/mm 3 ), regardless of use of ARVs.
Methods
This study is a secondary analysis of two studies conducted under the auspices of the UCSF International Nursing Network for HIV/AIDS Research (www.ucsf.edu/aidsnursing) ( Table 1 ). The first study, ''Self-Care Symptom Management in HIV/ AIDS'' (Study A) (Reynolds et al., 2007 ) was a descriptive cross-sectional study examining self-reported symptoms and self-care behaviors in 1217 HIV-infected men and women from Colombia, Norway, Puerto Rico, Taiwan and the USA. The second study, ''The Efficacy of the HIV/AIDS Symptom Management Manual'' (Study B) (Wantland et al., 2008) , was a three-month, repeated measures randomized controlled trial of 775 participants in Kenya, Puerto Rico, South Africa, and the USA. Only the baseline data are used in this analysis.
Instruments
A Demographic Survey booklet was used to collect information on personal and environmental characteristics (e.g. age, gender, whether participants had adequate income). Data on biological/physiological factors (e.g. whether participants had received an AIDS diagnosis, had comorbidities) were also collected.
The Revised Sign and Symptom Checklist for Persons with HIV Disease (SSC-HIVrev) (Holzemer, Hudson, Kirksey, Hamilton, & Bakken, 2001 ) was used to capture the frequency and intensity of 72 common HIV signs and symptoms experienced by the participant on the day the checklist is completed. Items were rated on a three-point Likert scale of 1 (mild), 2 (moderate), or 3 (severe). Reliability and validity of the instrument have been previously reported for a US sample (Holzemer et al., 2001) . A Chinese version has been tested with a Taiwanese sample (Tsai, Hsiung, & Holzemer, 2003) . Slightly different Spanish versions were used in Texas, Puerto Rico, and Colombia. In Africa, the English version was used. Researchers at each site confirmed the content validity of the versions.
Data analysis
Responses to the questionnaires were entered into Statistical Package for the Social Sciences (SPSS) for Windows Version 13.0 software (SPSS, 2005) . Descriptive statistics (i.e., means, standard deviations, frequencies, and percents) were used to examine demographic characteristics of the samples and the frequency and intensity of the symptoms. For the purposes of this analysis, gynecological signs and symptoms were excluded. The individuals' self-reported CD4 values were stratified into three groups: 0Á200, 201Á350 and 350 CD4 cells/mm 3 . In Study A, 26.8% of reporting participants had CD4 counts of 0Á200 cells/mm 3 ; 19.5% had counts of 201Á350 cells/ mm 3 ; and 53.7% had counts greater than 350 cells/ mm 3 . In Study B, 24.7% had CD4 counts of 0Á200 cells/mm 3 ; 21.1% had counts of 201Á350 cells/mm 3 ; and 54.1% had counts greater than 350 cells/mm 3 . Analysis of covariance (ANCOVA) compared the mean number and intensity of symptoms reported by the three groups, controlling for taking ARV medications at the time of the survey.
Findings

Symptom rankings
In both studies, the most frequently reported symptoms included both physical and psychosocial symptoms: fatigue, depression, and muscle aches. Table 2 shows the ranking of the 20 most frequently reported symptoms for both studies, with a frequency range of 33Á60%.
Symptoms by CD4 category
For Study A, the mean self-reported CD4 count was 433 (SD 0413) and the average symptom frequency was 18.3 (SD 016.8) ( Table 3 ). The mean number of symptoms by CD4 category was: 0Á200 cells/ AIDS Care 323 mm 3 019.9 (SD 017.5); 201Á350 cells/mm 3 017.5 (SD015.6); and 350 cells/mm 3 017.9 (SD016.9). Of those reporting (n0820), 21.3% (n0175) were not taking ARV medications. No differences were noted as to whether or not the participant was taking ARV medications and the frequency or intensity of symptoms reported. ANCOVA revealed a nonsignificant main effect of CD4 category on the frequency of reported symptoms (F(2, 820) 02.43, p00.12). There were no differences in the number of symptoms among the three levels of CD4 counts. There was a significantly lower report of symptom intensity for those presently taking ARVs compared to those not taking ARVs (F(1, 718) 07.42, p 00.007), however similar to symptom frequency, there was no significant difference between the CD4 categories in either ARV group (F(2, 718) 00.44, p00.64).
For Study B, the mean self-reported CD4 count was 407 (SD 0268) and the average symptom frequency was 20.9 (SD 018.3). The mean number of symptoms by CD4 category was: 0Á200 cells/ mm 3 021.0 (SD 017.7); 201Á350 cells/mm 3 021.7 (SD020.3); and 350 cells/mm 3 020.4 (SD017.8). Of those reporting, (n 0477), 27.6% (n 0132) were not taking ARV medications. Again, there was no effect on whether or not the participant was taking (Table 3) . Intensity of symptoms in both studies demonstrates a wide SD. This indicates a broad variation in how patients perceive and rate their symptom experience.
Discussion
The data from these studies demonstrate that the term ''asymptomatic'' HIV disease is not a valid term, as patients do experience symptoms regardless of their CD4 count or lack of OIs. The data also reveal that self-reported symptoms are present in individuals regardless of whether they are taking ARVs. Clearly, there are symptoms associated with all levels of CD4 classification. Based on developments in HIV treatment and care, and the findings reported here, the authors recommend that clinicians no longer use the term ''asymptomatic'' to define their HIV-positive clients' treatment needs. Clinicians should carefully interview patients as to the presence of symptoms regardless of CD4 count and should address symptom management. The wide variability of symptoms' intensity lends credence to further interview of the patients to explore their illness experience and seek methods to improve quality of life. The danger of labeling someone living with HIV infection as ''asymptomatic'' is the failure to recognize the constellation of symptoms they are experiencing, on or off ARVs, across the spectrum of CD4 counts. Clinical practice guidelines have been shown to be an effective means of improving the way clinicians manage patients, and it is important for HIV clinical practice guidelines to reflect the fact that HIV-positive people may experience symptoms throughout their disease, and that these must be managed to improve quality of life.
